Amiodarone and chronic lung fibrosis

Area of Science:

• Pulmonology
• Cardiology
• Pharmacology

Background:

• Amiodarone is a potent antiarrhythmic drug.
• Pulmonary fibrosis is a serious adverse effect of amiodarone.
• Lung function monitoring is crucial for patients on amiodarone therapy.

Purpose of the Study:

• To investigate the impact of amiodarone therapy on lung function in patients with pulmonary fibrosis.
• To assess the relationship between amiodarone treatment duration, dosage, and lung function.
• To evaluate the incidence of acute pulmonary fibrosis in amiodarone-treated patients.

Main Methods:

• Covariate analysis of lung function indices (transfer factor, transfer coefficient, membrane diffusion).
• Comparison between recently treated and long-term treated patient groups.
• Exclusion of patients with confounding factors affecting gas transfer.

Main Results:

• A non-significant trend towards reduced lung function was observed.
• A lower-than-expected incidence of acute pulmonary fibrosis was noted.
• No deterioration in lung function was found with increased amiodarone duration or dose.

Conclusions:

• Amiodarone therapy did not lead to statistically significant lung function deterioration in this patient cohort.
• The observed incidence of acute pulmonary fibrosis was lower than anticipated.
• Long-term amiodarone use did not correlate with worsening pulmonary function in patients with pulmonary fibrosis.